cvPipeline Launches Hypertension Device Sector at the American College of Cardiology 2012 Meeting, Providing Daily Updatin

CHICAGO & SANTA BARBARA, Calif.--(BUSINESS WIRE)-- MarketMonitors, Inc. (MMI), a provider of online business intelligence and analytic databases, announced today the international launch of its new Drug-Resistant Hypertension (HTN) sector for its cvPipeline™ service. This new sector of the cvPipeline online database solution for the medical device industry is the first to provide business executives, investors, and industry analysts with a unified, daily updated view of the R&D landscape and competitive status of drug-resistant hypertension medical devices in development.

The announcement was made at the American College of Cardiology meeting in Chicago, IL.

The new HTN sector on cvPipeline covers a rapidly emerging landscape of drug-resistant hypertension products and clinical trials, including:

  • Over 20 products focused on renal denervation, implantable devices, and neurostimulation
  • More than 60 preclinical and clinical trials with detailed information on protocols, target enrollment, endpoints, and investigators and updates as new information is released or published
  • 20 companies, 17 of which are privately held, with information on financing, management, and intellectual property
  • Reports on data and investigator insights presented at a variety of industry and scientific meetings, including CRT, ACC, ESH, ASH, EuroPCR, ESC, TCT, and AHA

“Given the rapid pace of change in the R&D landscape for HTN, this is a crucial time for investors and industry to gain access to a sophisticated business intelligence tool focused on this exciting new market,” said Hollis Call, CEO of MMI. “cvPipeline’s HTN sector provides a one-stop, up-to-date service helping to answer critical questions such as: Who is investing in HTN? Who are the newest HTN entrants and what is their U.S. IP portfolio? What differentiates earlier-stage HTN products? Which HTN products have entered clinicals and how do their trial protocols and results compare?”

Pricing and Availability

The HTN sector is now available for purchase, along with cvPipeline’s databases for Atrial Fibrillation, Chronic Heart Failure, Drug-Eluting Stents, Heart Valves (including TAVR), and Cardiac Rhythm Management. Various subscription packages and services are available. For more information, visit www.cvpipeline.com or email [email protected].

About cvPipeline

cvPipeline is a 24/7, web-based information management solution for tracking new product development in the medical device industry. cvPipeline combines proprietary technology and business processes that ensure comprehensive and systematic aggregation of information, with a powerful database model that organizes the details and links related information, along with customized tools and features that put all of this information at your fingertips. With over six years of service to the industry, cvPipeline is the go-to resource for marketing, business development, R&D, clinical research, and legal departments throughout the industry. Our customers include analysts and executives, large integrated device companies and small startups, and early-stage and late-stage investors.

About MarketMonitors

MarketMonitors, Inc. (MMI) (www.marketmonitors.com) provides online business intelligence and analytic databases to the medical device and biologics industries.



CONTACT:

MarketMonitors, Inc.
Eric Lehto, 415-845-4869
[email protected]

KEYWORDS:   United States  North America  California  Illinois

INDUSTRY KEYWORDS:   Technology  Software  Health  Biotechnology  Cardiology  Clinical Trials  Hospitals  Medical Devices  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.